Table 4.
Best fit model for distribution of the STAT4 SNP rs11889341 alleles in North American white control subjects and patients with SSc*
| SSc Registry cohort |
UT Division cohort |
SSc Registry + UT Division |
SSc Registry + UT Division + controls† |
|||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2n | A, % |
P | OR (95% CI) | 2n | A, % |
P | OR (95% CI) | P | OR (95% CI) | 2n | A, % |
P | OR (95% CI) | |
| Control subjects | 826 | 21.7 | 548 | 24.3 | 6,644 | 22.2 | ||||||||
| SSc patients | 1,466 | 26.4 | 0.03‡ | 1.30 (1.1–1.6) | 612 | 28.1 | 0.14 | 1.22 (0.9–1.6) | 0.012‡ | 1.27 (1.1–1.5) | 2,078 | 26.9 | 2.4 × 10−5‡ | 1.29 (1.2–1.5) |
| Limited cutaneous SSc | 914 | 25.5 | 0.06 | 1.24 (0.99–1.5) | 284 | 30.6 | 0.15‡ | 1.38 (1.0–1.9) | 0.021‡ | 1.28 (1.1–1.5) | 1,198 | 26.7 | 1.7 × 10−3‡ | 1.28 (1.1–1.5) |
| Diffuse cutaneous SSc | 488 | 28.1 | 0.03‡ | 1.41 (1.1–1.8) | 284 | 26.8 | 0.43 | 1.14 (0.8–1.6) | 0.03‡ | 1.30 (1.1–1.6) | 772 | 27.6 | 2.0 × 10−3‡ | 1.34 (1.1–1.6) |
| Antibodies | ||||||||||||||
| Anticentromere | 430 | 26.3 | 0.07 | 1.29 (0.98–1.7) | 154 | 31.2 | 0.08 | 1.41 (0.95–2.1) | 0.03‡ | 1.33 (1.1–1.7) | 584 | 27.6 | 0.009‡ | 1.34 (1.1–1.6) |
| Anti–topoisomerase I | 272 | 26.5 | 0.10 | 1.30 (0.9–1.8) | 72 | 23.6 | 0.90 | 1.04 (0.6–1.8) | 0.17 | 1.21 (0.9–1.6) | 344 | 25.9 | 0.10‡ | 1.23 (0.95–1.6) |
| Anti–RNA polymerase III | 298 | 26.8 | 0.07 | 1.33 (0.98–1.8) | 82 | 26.8 | 0.62 | 1.14 (0.7–1.9) | 0.07 | 1.28 (0.98–1.7) | 380 | 26.8 | 0.09‡ | 1.29 (1.01–1.8) |
*
ORs and 95% CIs are for carriage of the A allele. Control subjects were used as reference for all comparisons. See Table 2 for definitions.
†
Published frequencies in controls were ascertained for 2,635 white control subjects from the New York Cancer Project.
‡
Corrected for multiple model testing using the Bonferroni adjustment.